- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00244608
A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
January 21, 2011 updated by: AstraZeneca
A Comparison of the Inflammatory Control of Asthma Provided by One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg/Inhalation b.i.d. Plus As-needed Versus One Inhalation of Symbicort® Turbuhaler® 320/9 µg/Inhalation b.i.d. + One Inhalation of Pulmicort® Turbuhaler® 400 µg/Dose b.i.d. Plus Terbutaline Turbuhaler® 0.4 mg/Inhalation As-needed. A 12-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational, Phase IIIB Study in Adult Patients With Asthma, EOS
The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark
- Research Site
-
Ålborg, Denmark
- Research Site
-
Århus C, Denmark
- Research Site
-
-
-
-
-
Montpellier, France
- Research Site
-
Pessac, France
- Research Site
-
-
-
-
-
Hannover, Germany
- Research Site
-
Mainz, Germany
- Research Site
-
Marburg, Germany
- Research Site
-
-
-
-
-
Baraclado, Spain
- Research Site
-
Barcelona No. 40, Spain
- Research Site
-
Barcelona, No. 42, Spain
- Research Site
-
-
-
-
-
Göteborg, Sweden
- Research Site
-
Lund, Sweden
- Research Site
-
Stockholm, Sweden
- Research Site
-
Umeå, Sweden
- Research Site
-
Uppsala, Sweden
- Research Site
-
-
-
-
-
Glasgow, United Kingdom
- Research Site
-
Leicester, United Kingdom
- Research Site
-
London, United Kingdom
- Research Site
-
Manchester, United Kingdom
- Research Site
-
Newcastle-Upon-Tyne, United Kingdom
- Research Site
-
Southampton, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of asthma for at least 6 months
- Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one
Exclusion Criteria:
- Respiratory infection affecting asthma within 30 days prior to study
- Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to study
- Any significant disease or disorder that may jeopardize the safety of the patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Change in eosinophils in bronchial biopsies (first and last visit) and in sputum (5 times during the 12-month treatment period)
|
Secondary Outcome Measures
Outcome Measure |
---|
Immunopathology and remodeling in biopsies
|
Immunopathology and mediators in induced sputum
|
Severe asthma exacerbations (number of and time to first)
|
Forced expiratory volume in 1 second (FEV1)
|
As-needed use
|
Safety variables, including adverse events and vital signs
|
All variables assessed over the 12-month treatment period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Study Completion (Actual)
March 1, 2007
Study Registration Dates
First Submitted
October 25, 2005
First Submitted That Met QC Criteria
October 25, 2005
First Posted (Estimate)
October 27, 2005
Study Record Updates
Last Update Posted (Estimate)
January 24, 2011
Last Update Submitted That Met QC Criteria
January 21, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Sympathomimetics
- Budesonide
- Formoterol Fumarate
- Terbutaline
Other Study ID Numbers
- D5890C00003
- EudraCT no. 2004-004042-41
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Budesonide/Formoterol Turbuhaler
-
Meir Medical CenterUnknown
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseKorea, Republic of, Poland, Russian Federation, Vietnam, Philippines, Ukraine, Japan, Taiwan, India
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompleted
-
AstraZenecaCompleted
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Germany
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseGermany, Switzerland
-
AstraZenecaCompletedCOPD Method Evaluation | Chronic Obstructive Pulmonary Disease Method EvaluationUnited Kingdom, Sweden
-
Orion Corporation, Orion PharmaCompleted